Frequently Asked Questions

Zanax Healthcare is an integrated pharmaceutical and nutraceutical solutions company offering trading, turnkey projects, R&D, contract manufacturing, regulatory services and strategic advisory.

Our head office is in Thane, Maharashtra, with business and R&D liaison offices in Mumbai and Hyderabad.

Yes. We sign mutual non disclosure agreements before any detailed technical or commercial discussion.

Yes. We work with businesses of every size, from first time brand owners to large distributors and manufacturers.

Send an enquiry with your requirement. We will schedule a discovery call, understand your goals and share a tailored proposal.

We support shipments to Africa, Southeast Asia, CIS, Latin America and the Middle East, along with selected regulated markets depending on the product registration status.

Yes. We arrange private label and loan licence supply using your artwork, packaging specifications and registration requirements.

Typical documents include COA, COPP, free sale certificate, GMP certificate, packing list, commercial invoice and certificate of origin, based on what the destination country requires.

Minimum quantities depend on the product and pack size. We quote economical batch sizes for first orders and scale up as registrations and demand grow.

Yes. We coordinate pre-shipment inspection by the buyer's nominated agency or an independent inspector, along with sampling and certificate of conformity where required.

A typical oral solid dosage facility takes 12 to 24 months from design freeze to commercial production, depending on scale, approvals and site readiness.

Yes. We prepare URS documents, evaluate vendors, attend factory acceptance tests and manage installation and site acceptance.

Absolutely. We carry out gap assessments and plan upgrades that bring existing plants up to current GMP expectations with minimal production downtime.

We plan facilities for oral solids, oral liquids, topicals, injectables and nutraceutical formats, including multi product plants with segregated blocks.

Yes. We prepare layouts, documents and applications for manufacturing licences and support the site through inspections by the licensing authority.

For fully funded development projects, the formulation and associated data are transferred to the client as agreed in the development contract.

Yes. We develop tablets, capsules, powders, gummies, effervescent formats and liquids for nutraceutical and wellness brands.

Yes. We plan stability protocols for the ICH climatic zones relevant to your target markets, including Zone IVb.

Timelines vary by complexity. A simple generic formulation can take a few months to reach scale up, while modified release or novel formats take longer due to additional optimisation and stability work.

Yes. We characterise the reference product and develop an equivalent formulation, supported by comparative dissolution and analytical data.

MOQs depend on the dosage form and pack. We work with both startup brands and large distributors and will suggest the most economical batch size.

First orders typically take 30 to 45 days after artwork and sample approval, depending on material availability and batch size.

Yes. Client audits are welcome and we coordinate site visits and quality agreements before commercial production begins.

Yes. Our team can design or adapt artwork, cartons, labels and leaflets to meet regulatory requirements in your target market.

Yes. We manufacture to country specific requirements, including labelling language, pack formats and stability conditions for hot and humid climates.

CTD is the ICH format used by most regulated markets, while ACTD is the ASEAN variant with its own structure for quality, safety and efficacy sections. We prepare both.

Yes. We carry out gap assessments, prepare documentation and SOPs, train teams and support the site during inspection.

Yes. We handle post approval variations, renewals and periodic updates so your registrations remain valid.

If all data is available, a dossier can usually be compiled in a few weeks. Where stability, validation or bioequivalence data is missing, the timeline depends on generating that data.

Yes. We prepare dossiers for many emerging and regulated markets and support your local licence holder through submission and query responses.

Both. We advise promoters, private equity funds, family offices and strategic buyers evaluating opportunities in pharma and nutraceuticals.

Yes. We screen, shortlist and approach suitable partners and targets based on your criteria, while keeping your identity confidential.

Engagements can be retainer based, project based or success fee linked, depending on the scope and nature of the mandate.

We provide valuation inputs and industry benchmarks as part of deal support and work alongside registered valuers and financial advisors where formal valuations are required.

Yes. We assess operations, portfolio, compliance and costs, then build and support a practical turnaround plan with measurable milestones.